Tumor dependent growth kinetics of human tumor xenografts using the subrenal capsule assay

Edelstein, M; Smink, T.; Ruiter, D.J.; Putten, L.M. van

doi:10.1016/0277-5379(85)90006-9

Cited by 5 publications

(8 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After 3-4 days considerable necrosis, granulation tissue, and tissue absorption was observed, resulting in the subsequent loss of antigen and concomitant decrease in '2sI-TURP-27 binding (i.e., decrease in detectable radioactivity). The loss of viability of the prostate tumor implant after 3-4 days is in contrast to studies in which nude mouse transplantation implants of human tumors showed essentially the same growth rates whether implanted for 6 days in immunodeficient athymic nude mice or in normal immunocompetent mice [ 10,12,13]. Furthermore, microscopic and ultrastructural examinations of these transplantable human tumor xenografts showed that even after 6 days under the renal capsule of normal mice, the morphology of the parent tumor was retained.…”

Section: Discussionmentioning

confidence: 65%

Radiolocalization of human prostate tumor in a mouse subrenal capsule model by monoclonal antibody turp‐27

Wright

Wilson²,

Klinger³

et al. 1990

The Prostate

View full text Add to dashboard Cite

The subrenal capsule assay was used to determine if 125I-labeled anti-prostate monoclonal antibody TURP-27 could target human prostate tumor fragments implanted under the renal capsule of normal immunocompetent C57 BL/6 mice. Maximal binding and optimal tumor to non-tumor tissue ratios occurred within 24-48 hours postadministration of 125I-TURP-27. No significant localization was observed in mice bearing TURP-27 antigen-negative human colon tumor tissue implants or with an isotype-matched control monoclonal antibody. These preclinical data suggest that TURP-27 may have clinical application for imaging metastatic prostate tumors and further application in immunoconjugate and/or radiotherapy of prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 65%

Radiolocalization of human prostate tumor in a mouse subrenal capsule model by monoclonal antibody turp‐27

Wright

Wilson²,

Klinger³

et al. 1990

The Prostate

View full text Add to dashboard Cite

show abstract

“…Sometimes it takes more time for the tumor to adapt to the microenvironment of the area under the renal capsule, consequently entire tumor formation could not be completed within 24 hours post-implantation [3]. Given the characteristics of the implantation, histological data strengthened that the tumor forming procedure may take one-to-two days to be completed after implantation [5]. As a result, analysis performed on day 1 or 2 should be handled cautiously since early results may indicate anti-implantation effects of the tested drugs instead of anti-maturation [5].…”

Section: The History and Efficacy Of The Original Srca Methodsmentioning

confidence: 99%

“…Given the characteristics of the implantation, histological data strengthened that the tumor forming procedure may take one-to-two days to be completed after implantation [5]. As a result, analysis performed on day 1 or 2 should be handled cautiously since early results may indicate anti-implantation effects of the tested drugs instead of anti-maturation [5]. In the research series of Bogden et al, nude mice were administered treatment on day 1-10 and measurements of the implanted xenograft were performed on the day of the transplantation and on the 11 th day of the assay [3].…”

Section: The History and Efficacy Of The Original Srca Methodsmentioning

confidence: 99%

“…Early histological examinations pointed out the variability of the examined tumor fragments in the amount of fibrosis and the inward growth of host cells [13]. The extent of host cell growth into the tumors highlights the insignificant amount of histologically proven malignant cells inside the implantable fragments [5].…”

Section: Human-derived Srca Tumor Modelsmentioning

confidence: 99%

“…Since physiological host immune reaction can result in the measurement of the chemotherapeutic agent induced immunosuppression instead of the desired antitumor effect of the molecule, SRCA was further developed by the administration of anti-inflammatory molecules, cortisone pre-treatment, or whole-body irradiation prior to the implantation itself [5,14]. Data are available about the necessity of the application of either pre-implantation treatment or other modifications to inhibit the occurrence of host cell ingrowth into the tumors [3].…”

Section: Human-derived Srca Tumor Modelsmentioning

confidence: 99%

See 2 more Smart Citations

Subrenal Capsule Assay - SRCA: The Promising Re-Emergence of a Long-Forgotten Method in Preclinical Nuclear Medical Cancer Diagnostics

Képes¹,

Trencsényi²

2023

J. Cancer

View full text Add to dashboard Cite

Since metastases are responsible for the majority of cancer-related death, in-depth understanding of metastatisation may provide an opportunity for the introduction of new therapeutic as well as diagnostic approaches in cancer management. Previously, preclinical research into the development and progression of malignancies has been hampered by the relative paucity of in vivo tumor models. Subrenal capsule assay (SRCA)-induced tumor-bearing experimental animal models, however, serve as potential preclinical model systems for the assessment of primary tumors and the route of metastatic spread. Several studies implementing either Hepatocarcinoma (He/De), Mesoblastic Nephroma (Ne/De), chemically induced Myeloid Leukemia (My1/De), or spontaneous Myeloid Myelomonocytic Leukemia (My2/De) cells under the left renal capsule of rats applying SRCA method were underway to study secondary tumor formation. Based on the results of this research, subrenally transplanted neoplastic cells led to the appearance of metastasis in the parathymic lymph nodes. Therefore, renal capsule/parathymic lymph node complex seems to be valuable in the in vivo evaluation of the process of metastatisation and the occurrence of secondary neoplasms. The re-emergence of this highly promising SRCA-based renal capsule/parathymic lymph node complex in preclinical nuclear medicine and experimental oncology may open a novel field towards drug trials and radiopharmaceutical development. In the present review, we provide a detailed overview of the history of SRCA as well as the series of research on the establishment of renal capsule/parathymic lymph node complex.

show abstract

Mitotic index in the subrenal capsule assay as an indicator of the chemosensitivity of ovarian cancer

Suonio

Lipponen

Mäenpää

et al. 1997

Cancer Chemotherapy and Pharmacology

View full text Add to dashboard Cite

The subrenal capsule assay (SRCA) is used in clinical oncology to assess the sensitivity of individual malignant tumors to various anticancer agents and their combinations. Mitotic indices reflect cancer cell proliferation and have prognostic value in epithelial neoplasms, including ovarian carcinoma. We combined the two tests (SRCA, mitotic index) by evaluating the numbers of mitotic figures per square millimeter of neoplastic epithelium (M/V) in paraffin-embedded tumor samples after SRCA. The M/V index was compared with the tumor size measurement (dTS), which is used in conventional SRCA to predict the drug response. Histology examination showed insignificant changes in the size of tumor transplants due to host reaction but disclosed a number of potential errors in the use of dTS to evaluate transplant growth and drug effects. In our series of 62 patients with advanced ovarian carcinoma the M/V value was superior to the dTS in explaining the clinical response after 6 months as assessed at second-look laparotomy. Patients showing no response had significantly higher M/V values than did those displaying complete or partial responses (P < 0.033). The use of 6 mitotic figures/mm2 as a limit differentiating responders from nonresponders resulted in an overall predictive accuracy of 79% in the logistic regression analysis. In comparison to the FIGO stage, residual tumor size, and the dTS, the M/V value obtained for the cytostatic combination given to the patient was the single most significant factor predicting the 6-month clinical response. The results indicate that the combined use of the M/V index and SRCA is a promising new approach to prediction of the drug response in ovarian adenocarcinoma.

show abstract

Tumor dependent growth kinetics of human tumor xenografts using the subrenal capsule assay

Cited by 5 publications

References 3 publications

Radiolocalization of human prostate tumor in a mouse subrenal capsule model by monoclonal antibody turp‐27

Radiolocalization of human prostate tumor in a mouse subrenal capsule model by monoclonal antibody turp‐27

Subrenal Capsule Assay - SRCA: The Promising Re-Emergence of a Long-Forgotten Method in Preclinical Nuclear Medical Cancer Diagnostics

Mitotic index in the subrenal capsule assay as an indicator of the chemosensitivity of ovarian cancer

Contact Info

Product

Resources

About